Cardiff Oncology, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CRDF moving today?
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CRDF.
CRDF insider activity
Cardiff Oncology, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CRDF.
CRDF contract awards, year to date.
Public federal awards linked to this ticker.
CRDF lobbying filings, year to date.
Registered lobbying filings matched to Cardiff Oncology, Inc. Common Stock.